Other languages Johnson & Johnson Borsa Italiana

Equities

4JNJ

US4781601046

End-of-day quote Borsa Italiana Other stock markets 18:00:00 2024-06-03 EDT			5-day change	1st Jan Change
134.9 ^EUR	-0.81%		+0.97%	-4.07%

01:51am	J&J-backed Rapport Therapeutics raises $136 mln in US IPO	RE
06-06	Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

J&J-backed Rapport Therapeutics raises $136 mln in US IPO	07:51pm
Borsa di Italia: Verso l'infinito e oltre	06-06
Bolsa de Madrid: Hasta el infinito y más allá	06-06
J&J : sollicite la FDA une indiation élargie du Prezcobix	06-05
J&J : essai concluant pour Carvykti dans le myélome multiple	06-04
J&J : essai prometteur pour Tecvayli dans le myélome multiple	06-04
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	06-04
Borsa di Italia: Mai contenti!	06-04
J&J must pay $260 million in latest talc trial, Oregon jury says	06-03
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	06-03
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	06-03
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	06-03
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	06-03
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	06-03
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	06-03
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	06-03
GSK blood cancer drug nearly halves risk of death in late-stage trial	06-02
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	06-01
Johnson & Johnson Announces First Data from the Phase 3 PALOMA-3 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib	05-31
Sector Update: Health Care Stocks Higher Late Afternoon	05-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm